MEDICAL PRESS | Biomarker indicates tumor aggressiveness and poor prognosis in men with prostate cancer

News

Published: 12Jun2019

Mortality due to prostate cancer is usually related to its likelihood to metastasize, especially to bone. Prognostic biomarkers are urgently needed to predict disease aggression so that appropriate treatment can be selected. A report in The American Journal of Pathology, published by Elsevier, indicates that CCN3, a protein secreted into the extracellular matrix between cells, may be an important factor that promotes prostate cancer invasion of bone and may aid in identifying prostate cancer patients at higher risk of poor outcomes.

"Our work indicates that CCN3 functions to promote the formation of prostate cancerbone metastases and supports its use, after further validation, as a biomarker that predicts metastasis to bone," said lead investigator Peter M. Siegel, Ph.D., of the Goodman Cancer Research Centre, McGill University, Montreal, Canada. 

Read more

Tags: